US Bancorp DE Sells 21,641 Shares of Solventum Corporation $SOLV

US Bancorp DE cut its position in Solventum Corporation (NYSE:SOLV) by 4.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 451,102 shares of the company’s stock after selling 21,641 shares during the quarter. US Bancorp DE’s holdings in Solventum were worth $34,212,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Chelsea Counsel Co. raised its holdings in Solventum by 720.7% in the second quarter. Chelsea Counsel Co. now owns 10,595 shares of the company’s stock worth $804,000 after purchasing an additional 9,304 shares in the last quarter. ST Germain D J Co. Inc. raised its holdings in Solventum by 84.6% in the second quarter. ST Germain D J Co. Inc. now owns 825 shares of the company’s stock worth $63,000 after purchasing an additional 378 shares in the last quarter. CX Institutional raised its holdings in Solventum by 11.7% in the second quarter. CX Institutional now owns 2,376 shares of the company’s stock worth $180,000 after purchasing an additional 249 shares in the last quarter. ORG Wealth Partners LLC bought a new position in Solventum in the second quarter worth about $71,000. Finally, Public Employees Retirement System of Ohio raised its holdings in Solventum by 0.9% in the second quarter. Public Employees Retirement System of Ohio now owns 63,719 shares of the company’s stock worth $4,832,000 after purchasing an additional 583 shares in the last quarter.

Solventum Price Performance

Shares of NYSE:SOLV opened at $70.53 on Friday. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. Solventum Corporation has a twelve month low of $60.70 and a twelve month high of $85.92. The company’s 50 day moving average is $72.75 and its 200 day moving average is $72.11. The company has a market cap of $12.23 billion, a PE ratio of 32.65, a price-to-earnings-growth ratio of 2.92 and a beta of 0.50.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping the consensus estimate of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The business had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.12 billion. During the same quarter in the prior year, the firm posted $1.56 EPS. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, sell-side analysts forecast that Solventum Corporation will post 6.58 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on SOLV shares. UBS Group started coverage on shares of Solventum in a report on Wednesday, October 1st. They set a “neutral” rating and a $77.00 price objective on the stock. Wall Street Zen downgraded shares of Solventum from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 9th. Zacks Research upgraded shares of Solventum from a “hold” rating to a “strong-buy” rating in a report on Monday, September 15th. Argus upgraded shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 price objective on the stock in a report on Tuesday, July 1st. Finally, Wells Fargo & Company upped their price objective on shares of Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a report on Monday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $84.89.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.